3rd Annual Covalent Drug Discovery and Development Summit

3rd Annual Covalent Drug Discovery and Development Summit is organized by Hanson Wade and will be held from Dec 09 - 11, 2025 at Revere Hotel Boston Common, 200 Stuart St, Boston, Massachusetts, United States of America.

Description:
The 3rd Covalent Drug Discovery and Development Summit returns as the premier industry forum for experts to accelerate the discovery, translation and development of covalent drugs, driving the next wave of first- and best-in-class therapeutics against previously undruggable targets.

Uniting covalent drug leaders from the likes of Vividion Therapeutics, Pfizer, Revolution Medicines and Frontier Medicines, this three day deep-dive forum will focus on:

• Optimizing warhead selectivity, reactivity and durability to ensure the development of tolerable, potent covalent therapies
• Targeting non-cysteine residues and hard-to-drug proteins including transcription factors to expand the druggable proteome
• Elucidating PK/PD relationships and understanding ADME and target engagement to inform dosing and streamline clinical development
• Innovating advanced screening technologies and lead optimization strategies to rationally triage hits and progress covalent candidates efficiently

Over 3 days, join 80+ leaders in medicinal chemistry, biochemistry, structural biology and translation to uncover insights on overcoming key challenges in warhead design, lead optimization and preclinical to clinical development, ensuring that your pipeline is de-risked to reach patients in need.

Speakers: Andreas Goutopoulos, CEO, actithera, Brendan Hilbert, Director of Protein and Structural Sciences, Antares Therapeutics, Brian Cook, Vice President and Head of Early Discovery Chemistry, Vividion Therapeutics, Chris Haggard, Co-Founder and CTO, Axiom Therapeutics, Daniel Nomura, Professor - Chemical Biology and Molecular Therapeutics, University of California at Berkeley, Daniele Canzani, Senior Scientist, Talus Bio, Fiona Pachl, Associate Principal Scientist - Chemical Biology and Proteomics, AstraZeneca, Ivan Cornella-Taracido Chief Scientific Officer, Covant Therapeutics, Jacob Stuckey, Vice President - Biochemistry and Chemical Biology, Flare Therapeutics, Jared Cumming, Chief Scientific Officer, Matchpoint Therapeutics, John (Jianwei) Che, Core Director, Dana-Farber / Harvard Cancer Center, Lata Jayaraman, Head Senior VP, Oncology and Inflammation Research, Frontier Medicines, Laura D'Agostino, VP Chemistry, Monimoi Therapeutics, Markus Schirle, Executive Director, Novartis AG, Matthew Labenski, Senior Director - Proteomics and Chemical Biology, Jnana Therapeutics, Ning Deng, Director, IMTAC Discovery, BridGene Biosciences Inc., Paramita Deria, Discovery Chemistry Professional, Bayer, Sean Toenjes, Executive Director, Chemistry and Innovation, Aethon Therapeutics, Sujata Chakraborty, Senior Scientist, Revolution Medicines, Tangpo Yang, Principal Scientist, Pfizer, Uthpala Seneviratne, Associate Principal Scientist, AstraZeneca